Heterogeneity of treatment effect in SPRINT by age and baseline comorbidities: The greatest impact of intensive blood pressure treatment is observed among younger patients without CKD or CVD and in older patients with CKD or CVD. Issue 9 (16th August 2020)

• Record Type: Journal Article
• Authors: Rostomian, Ara H.; Tang, Maxine C.; Soverow, Jonathan; Sanchez, Daniel R.
• Is Part Of: Journal of clinical hypertension. Volume 22:Issue 9(2020)
• Page Start: 1723
• Page End: 1726
• Publication Date: 2020-08-16
• Subjects: Hypertension -- Periodicals; 616.132
• DOI: 10.1111/jch.13955
• Languages: English
• ISSNs: 1524-6175

Abstract

Abstract: The Systolic Blood Pressure Intervention Trial (SPRINT), a large randomized controlled trial funded by the National Institutes of Health, randomized 9361 patients with hypertension over 50 years of age and at least one cardiovascular risk factor to intensive (SBP < 120 mm Hg) or standard (SBP < 140 mm Hg) blood pressure treatment. The trial found a significant reduction in primary cardiovascular and mortality outcomes in the intensive treatment group. We performed an IRB‐approved post hoc analysis of the SPRINT trial data, recently made available through the NEJM SPRINT Data Analysis Challenge. Our subgroup analysis stratified subjects by age (≥75 years vs. <75 years) and presence or absence of pre‐existing chronic kidney disease (CKD) or cardiovascular disease (CVD). We found that intensive blood pressure control was associated with a significantly lower rate of the primary CVD outcome and all‐cause mortality in subjects age <75 years with no prior CVD or CKD and in subjects age ≥75 years with pre‐existing CVD or CKD.